Teleflex Reports Better Than Expected Q4 Earnings, Issues Mixed FY22 Guidance
Teleflex Incorporated (NYSE: TFX) reported
Expert Ratings For Teleflex
Within the last quarter, Teleflex (NYSE:TFX) has observed the following analyst ratings:
Raymond James Maintains Outperform on Teleflex, Lowers Price Target to $370
Raymond James analyst Jayson Bedford maintains Teleflex (NYSE:TFX) with a Outperform and lowers the price target from $391 to $370.
Needham Maintains Buy on Teleflex, Lowers Price Target to $400
Needham analyst Mike Matson maintains Teleflex (NYSE:TFX) with a Buy and lowers the price target from $425 to $400.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Morgan Stanley Downgrades Teleflex to Equal-Weight, Lowers Price Target to $383
Morgan Stanley analyst Cecilia Furlong downgrades Teleflex (NYSE:TFX) from Overweight to Equal-Weight and lowers the price target from $431 to $383.
Where Teleflex Stands With Analysts
Analysts have provided the following ratings for Teleflex (NYSE:TFX) within the last quarter:
Piper Sandler Downgrades Teleflex to Neutral, Lowers Price Target to $325
Piper Sandler analyst Matt O'Brien downgrades Teleflex (NYSE:TFX) from Overweight to Neutral and lowers the price target from $465 to $325.
Wells Fargo Maintains Overweight on Teleflex, Lowers Price Target to $355
Wells Fargo analyst Larry Biegelsen maintains Teleflex (NYSE:TFX) with a Overweight and lowers the price target from $450 to $355.
Teleflex Receives Reimbursement Approval For The UroLift System In Japan
Teleflex Incorporated (NYSE:TFX) today announced that the company has received reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo) of its UroLift System for patients who require